Pros and cons of off-label promotion investigations and prosecutions

Food and Drug Law Journal

Volumn 61, Issue 3, 2006, Pages

  Loucks, Michael K ^a  

^a United States Attorney's Office for the District of Massachusetts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GABAPENTIN; ROFECOXIB;

ACT; CONFERENCE PAPER; DRUG APPROVAL; DRUG INDUSTRY; FALSE CLAIMS ACT; FOOD AND DRUG ADMINISTRATION; FOOD DRUG AND COSMETIC ACT; GOVERNMENT; HEALTH PROMOTION; LAW; LAW SUIT; MEDICAL STUDENT; OFF LABEL DRUG USE; PHYSICIAN; SAFETY;

CONSUMER PRODUCT SAFETY; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HUMANS; LEGISLATION, DRUG; MARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748929666     PISSN: 1064590X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Shweta Namjoshi, A Primer on Off-Label Marketing of Pharmaceuticals: Revitalizing Professionalism: AMSA's PharmFree Initiative, edited by Leana S. Wen, AMSA National President 2005-2006, American Medical Student Association (http://www.amsa.org/hp/2005OffLabel_Marketing.pdf).